Paper498148
Rationale for development of platinum analogs.
Burchenal JH and 3 others. Cancer Treat Rep, 1979. Cited by 116 papers, by iCite.
Cite this record
ConductScience Library. Rationale for development of platinum analogs. Papers, record 498148. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/498148
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| Leukemia, Experimental | Major topic |
| Animals | |
| Cyclohexylamines | |
| Drug Evaluation, Preclinical | |
| Drug Resistance | |
| Drug Synergism | |
| Drug Therapy, Combination | |
| Mice | |
| Organoplatinum Compounds | |
| Thiourea |
Source PubMed
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 116 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37454081 | Study of novel bidentate heterocyclic amine-based metal complexes and their biological activities: cytotoxicity and antimicrobial activity evaluation. | BMC Chem | 2023 | https://conductscience.org/library/papers/37454081 | PubMed |
| 36290786 | Prevention of Testicular Damage by Indole Derivative MMINA via Upregulated StAR and CatSper Channels with Coincident Suppression of Oxidative Stress and Inflammation: In Silico and In Vivo Validation. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/36290786 | PubMed |
| 28003740 | Dose-dependent effects of cisplatin on the severity of testicular injury in Sprague Dawley rats: reactive oxygen species and endoplasmic reticulum stress. | Drug Des Devel Ther | 2016 | https://conductscience.org/library/papers/28003740 | PubMed |
| 26691229 | The effects of MOTILIPERM on cisplatin induced testicular toxicity in Sprague-Dawley rats. | Cancer Cell Int | 2015 | https://conductscience.org/library/papers/26691229 | PubMed |
| 24874729 | Systems biology of cisplatin resistance: past, present and future. | Cell Death Dis | 2014 | https://conductscience.org/library/papers/24874729 | PubMed |
| 15726120 | Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. | Br J Cancer | 2005 | https://conductscience.org/library/papers/15726120 | PubMed |
| 9472630 | In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9472630 | PubMed |
| 8080724 | Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. | Br J Cancer | 1994 | https://conductscience.org/library/papers/8080724 | PubMed |
| 7981487 | New platinum agents. A comparison in ovarian cancer. | Drugs Aging | 1994 | https://conductscience.org/library/papers/7981487 | PubMed |
| 7850917 | Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II). | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7850917 | PubMed |
| 7031350 | [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. | Klin Wochenschr | 1981 | https://conductscience.org/library/papers/7031350 | PubMed |
| 3935149 | Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes. | Br J Cancer | 1985 | https://conductscience.org/library/papers/3935149 | PubMed |
| 3910609 | Comparative cytotoxicity between cisplatin and second generation platinum analogs. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/3910609 | PubMed |
| 3293840 | Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3293840 | PubMed |
| 3048763 | Resistance to cisplatin and analogues: mechanisms and potential clinical implications. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3048763 | PubMed |
| 2803953 | Cisplatin/carboplatin cross-resistance in ovarian cancer. | Br J Cancer | 1989 | https://conductscience.org/library/papers/2803953 | PubMed |
| 2679841 | Acute and cumulative effects of carboplatin on renal function. | Br J Cancer | 1989 | https://conductscience.org/library/papers/2679841 | PubMed |
| 2653399 | Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. | Br J Cancer | 1989 | https://conductscience.org/library/papers/2653399 | PubMed |
| 2229134 | Sensitivity of rodent osteosarcoma clones to platinum-containing phosphonic acid complexes in vitro. | J Cancer Res Clin Oncol | 1990 | https://conductscience.org/library/papers/2229134 | PubMed |
| 1906857 | Toxicological and tumoricidal evaluations of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)platinum( II) monohydrate, in rats. | Jpn J Cancer Res | 1991 | https://conductscience.org/library/papers/1906857 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/498148
GET https://conductscience.org/api/papers/v1/498148/cited_by?page=2